[1] |
Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)[J]. Pediatr Int, 2020, 62(10): 1135-1138.
doi: 10.1111/ped.v62.10
|
[2] |
中华医学会儿科学分会心血管学组, 中华儿科杂志编辑委员会. 川崎病冠状动脉病变的临床处理建议(2020年修订版)[J]. 中华儿科杂志, 2020, 58(9): 718-724.
|
[3] |
何学华, 朱潜力, 袁勇华, 等. 川崎病合并冠状动脉瘤患儿应用华法林治疗的安全性[J]. 中华儿科杂志, 2021, 59(2): 95-100.
|
[4] |
Newburger JW, Burns JC, Beiser AS, et al. Altered lipid profile after Kawasaki syndrome[J]. Circulation, 1991, 84(2): 625-631.
doi: 10.1161/01.cir.84.2.625
pmid: 1860206
|
[5] |
Yoshioka T, Matsutani T, Iwagami S, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease[J]. Immunology, 1999, 96(3): 465-472.
pmid: 10233729
|
[6] |
Hourigan ST, Solly EL, Nankivell VA, et al. The regulation of miRNAs by reconstituted high-density lipoproteins in diabetes-impaired angiogenesis[J]. Sci Rep, 2018, 8(1): 13596.
doi: 10.1038/s41598-018-32016-x
pmid: 30206364
|
[7] |
Yeom JS, Woo HO, Park JS, et al. Kawasaki disease in infants[J]. Korean J Pediatr, 2013, 56(9): 377-382.
doi: 10.3345/kjp.2013.56.9.377
pmid: 24223598
|
[8] |
Fernandez-Cooke E, Barrios Tascón A, Sánchez-Manubens J, et al. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group[J]. PLoS One, 2019, 14(5): e0215665.
|
[9] |
王复娟, 吴良霞. 川崎病冠状动脉损害相关危险因素分析[J]. 临床儿科杂志, 2020, 38(7): 481-484.
|
[10] |
Peng Y, Liu X, Duan Z, et al. Age-related differences in clinical characteristics of Kawasaki disease[J]. Braz J Med Biol Res, 2021, 54(3): e10281.
|
[11] |
Shao S, Zhou K, Liu X, et al. Predictive value of serum lipid for intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease[J]. J Clin Endocrinol Metab, 2021, 106(10): e4210-e4220.
doi: 10.1210/clinem/dgab230
pmid: 33837779
|
[12] |
廖先华, 许玉霞, 刘增荣. 川崎病患儿血脂代谢与冠状动脉病变的关系[J]. 华西医学, 2010, 25(6): 1036-1038.
|